title: Lenalidomide for bortezomib-resistant multiple myeloma.
authors.forename: Chiara
authors.initials: C
authors.lastname: Briani
authors.forename: Tamara
authors.initials: T
authors.lastname: Berno
authors.forename: Marta
authors.initials: M
authors.lastname: Campagnolo
authors.forename: Renato
authors.initials: R
authors.lastname: Zambello
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm; D006305:Health Status Indicators; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide
references.citation: Nat Rev Clin Oncol. 2010 May;7(5):289-94
references.pmid: 20351701
references.citation: Cancer. 2007 Sep 1;110(5):1042-9
references.pmid: 17654660
references.citation: J Peripher Nerv Syst. 2007 Sep;12(3):210-5
references.pmid: 17868248
references.citation: Neurology. 2009 Sep 8;73(10):812-3
references.pmid: 19738177
references.citation: Expert Opin Pharmacother. 2009 Jan;10(1):125-33
references.pmid: 19236186
references.citation: Neurology. 2004 Jun 22;62(12):2288-90
references.pmid: 15210897